

Product datasheet for TL507124V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

C1qtnf5 Mouse shRNA Lentiviral Particle (Locus ID 235312)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: C1qtnf5 Mouse shRNA Lentiviral Particle (Locus ID 235312)

Locus ID: 235312

Synonyms: Adie; CTR; Ctrp5; Mfrp

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: C1qtnf5 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: BC023068, BC025174, NM 001040631, NM 001040632, NM 001190313, NM 001190319,

NM 145613, NM 001040631.1, NM 001040631.2, NM 001190319.1, NM 145613.1, NM 145613.2, NM 145613.3, NM 145613.4, NM 001190313.1, NM 001040632.1,

NM 001040632.2

UniProt ID: Q8K479

Summary: The protein encoded by this gene is a member of the C1q/tumor necrosis factor superfamily.

This family member is a secretory protein that functions in eye development. Mutations in this gene are thought to underlie the pathophysiology of late-onset retinal degeneration (L-ORD) and early-onset long anterior zonules (LAZ). Bicistronic transcripts composed of the coding sequences for this gene (C1qtnf5) and the membrane-type frizzled-related protein gene (Mfrp) have been identified, and the resulting products can interact with each other. Cotranscription of C1qtnf5 and Mfrp has been observed in both human and mouse. Alternative

splicing results in multiple transcript variants. [provided by RefSeq, Jun 2010]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).